“We’re excited to renew our partnership with UMass Amherst and its world-renowned research faculty to continue developing a targeted, localized therapy that could address an unmet medical need in rheumatoid arthritis,” said Dr. Charles H. Sherwood, PSE alum '77 and chief executive officer of Anika Therapeutics.
A new agreement to extend a two-year strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc., of Bedford, Mass., a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, and the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst.
In the next phase of this collaboration, Anika and UMass will focus on research to optimize the drug delivery system with the goal of advancing a novel therapeutic candidate into clinical trials to support regulatory submission.